EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Outcomes of Inhaled Treprostinil in Pulmonary Hypertension Related to Interstitial Lung Disease: A Multicenter, Retrospective Analysis

Andrew R Kyle iD, Arun Jose iD, Kristen Catherman, Jean Elwing iD, Roxana Sulica, Gerald S Zavorsky iD, Namita Sood

Journal of Cardiovascular Development and Disease · 10.03.2026 · 13 (3) · 129

DOI: 10.3390/jcdd13030129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 10.03.2026. Verfasst von Andrew R Kyle und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, and Sleep Medicine, University of California-Davis, Sacramento, CA 95817, USA. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH NHLBI K23 career development grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhaled Treprostinil is the primary treatment of pulmonary hypertension related to interstitial lung disease (PH-ILD). Despite treatment effectiveness in clinical trials, the real-world safety and tolerability of this therapy remains unclear. We conducted a multicenter, retrospective review of adults with PH-ILD who were prescribed inhaled treprostinil. We assessed clinical outcomes, 6 min walk distance (6MWD) and changes in natriuretic peptides (BNP, NT-proBNP), as well as medication tolerance. Eighty-three patients met the inclusion criteria. The 6MWD data was collected but a limited number of patients had results within close proximity to initiation of inhalational treprostinil with only seven patients having assessments within the 3 months prior to initiation as well as 3 months post therapy. Limited 6MWD data is likely due, in part, to coinciding with the COVID pandemic, limiting face-to-face interactions and exercise testing. The majority of our subjects, 63%, had an absolute improvement in their BNP level, over a mean duration of 170 days. However, no significant difference was detected between baseline and follow-up natriuretic peptide levels. Adherence was assessed and the majority (77%) of patients remained on therapy at the time of censoring, with three-quarters (75%) meeting the target dose. Of the 15 patients intolerant to nebulized treprostinil who were transitioned to a dry powder inhaler, the majority (87%) were able to tolerate the other formulation. The medication was well-tolerated with a large percentage of patients remaining on therapy indefinitely and reaching the targeted therapeutic dose.

Schlagwörter

Stichwörter der Autor:innen

inhaled treprostinilinterstitial lung diseasepulmonary hypertension

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care, and Sleep Medicine, University of California-Davis, Sacramento, CA 95817, USA.
  • Division of Pulmonary and Critical Care Medicine, University of Cincinnati, Cincinnati, OH 45219, USA.
  • Division of Pulmonary and Critical Care Medicine, New York University Langone Health, New York, NY 10016, USA.
  • Department of Physiology and Membrane Biology, University of California-Davis, Davis, CA 95616, USA.

ORCID-Profile: Andrew R Kyle, Arun Jose, Jean Elwing, Gerald S Zavorsky

Förderung

  • NIH NHLBI K23 career development grant

Zitieren

APA

Kyle, A. R., Jose, A., Catherman, K., Elwing, J., Sulica, R., Zavorsky, G. S., & Sood, N. (2026). Real-World Outcomes of Inhaled Treprostinil in Pulmonary Hypertension Related to Interstitial Lung Disease: A Multicenter, Retrospective Analysis. Journal of Cardiovascular Development and Disease, 13(3), 129. https://doi.org/10.3390/jcdd13030129

Vancouver

Kyle AR, Jose A, Catherman K, Elwing J, Sulica R, Zavorsky GS, et al. Real-World Outcomes of Inhaled Treprostinil in Pulmonary Hypertension Related to Interstitial Lung Disease: A Multicenter, Retrospective Analysis. Journal of Cardiovascular Development and Disease. 2026;13(3):129. doi:10.3390/jcdd13030129

BibTeX
@article{Kyle2026,
  author = {Kyle, Andrew R and Jose, Arun and Catherman, Kristen and Elwing, Jean and Sulica, Roxana and Zavorsky, Gerald S and Sood, Namita},
  title = {Real-World Outcomes of Inhaled Treprostinil in Pulmonary Hypertension Related to Interstitial Lung Disease: A Multicenter, Retrospective Analysis},
  journal = {Journal of Cardiovascular Development and Disease},
  year = {2026},
  volume = {13},
  number = {3},
  pages = {129},
  doi = {10.3390/jcdd13030129}
}
Kostenlos starten →